|Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer|
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
|Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline|
AA Wright, K Bohlke, DK Armstrong, MA Bookman, WA Cliby, ...
Gynecologic oncology 143 (1), 3-15, 2016
|Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations|
R Salani, FJ Backes, MFK Fung, CH Holschneider, LP Parker, RE Bristow, ...
American journal of obstetrics and gynecology 204 (6), 466-478, 2011
|Identification of six new susceptibility loci for invasive epithelial ovarian cancer|
KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ...
Nature genetics 47 (2), 164-171, 2015
|Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study|
D Tewari, JJ Java, R Salani, DK Armstrong, M Markman, T Herzog, ...
Obstetrical & Gynecological Survey 70 (8), 505-506, 2015
|Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial cancer|
ME Randall, V Filiaci, DS McMeekin, V Von Gruenigen, H Huang, ...
Journal of Clinical Oncology 37 (21), 1810, 2019
|An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations|
R Salani, N Khanna, M Frimer, RE Bristow, L Chen
Gynecologic oncology 146 (1), 3-10, 2017
|Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome|
R Salani, A Santillan, ML Zahurak, RL Giuntoli, GJ Gardner, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
|Cancer and pregnancy: an overview for obstetricians and gynecologists|
R Salani, CC Billingsley, SM Crafton
American journal of obstetrics and gynecology 211 (1), 7-14, 2014
|Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug …|
R Salani, RJ Kurman, R Giuntoli, G Gardner, R Bristow, TL Wang, IM Shih
International Journal of Gynecologic Cancer 18 (3), 2008
|Amplicon profiles in ovarian serous carcinomas|
K Nakayama, N Nakayama, N Jinawath, R Salani, RJ Kurman, IM Shih, ...
International journal of cancer 120 (12), 2613-2617, 2007
|A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival|
K Nakayama, N Nakayama, B Davidson, JJC Sheu, N Jinawath, ...
Proceedings of the National Academy of Sciences 103 (49), 18739-18744, 2006
|Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status|
R Salani, I Puri, RE Bristow
American journal of obstetrics and gynecology 200 (2), 182. e1-182. e5, 2009
|BRCA mutation in ovarian cancer: testing, implications and treatment considerations|
RT Neff, L Senter, R Salani
Therapeutic advances in medical oncology 9 (8), 519-531, 2017
|Breast and gynecologic cancer-related extremity lymphedema: a review of diagnostic modalities and management options|
P Tiwari, M Coriddi, R Salani, SP Povoski
World journal of surgical oncology 11, 1-13, 2013
|Do survivorship care plans impact patients' evaluations of care? A randomized evaluation with gynecologic oncology patients|
BM Brothers, A Easley, R Salani, BL Andersen
Gynecologic oncology 129 (3), 554-558, 2013
|Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer|
R Salani, A Axtell, M Gerardi, C Holschneider, RE Bristow
Gynecologic oncology 108 (2), 271-275, 2008
|Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival|
CM Cosgrove, DE Cohn, H Hampel, WL Frankel, D Jones, JP McElroy, ...
Gynecologic oncology 146 (3), 588-595, 2017
|Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants|
DR Barnes, MA Rookus, L McGuffog, G Leslie, TM Mooij, J Dennis, ...
Genetics in Medicine 22 (10), 1653-1666, 2020
|NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021: Featured Updates to the NCCN Guidelines|
NR Abu-Rustum, CM Yashar, K Bradley, SM Campos, J Chino, HS Chon, ...
Journal of the National Comprehensive Cancer Network 19 (8), 888-895, 2021